NuCana won a European patent: what it means for NuCana stock

Published on 10/16/2026 at 01:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

NuCana won a European patent on September 30, 2026. NuCana stock now has more than 85 issued patents and funding planned into 2029.

Pipeline and balance sheet markers

NuCana announced the European patent on September 30, 2026, taking NUC-7738 protection beyond 85 issued patents.
The company reported a USD 3.08 million net loss for the second quarter of 2026.
NuCana had a USD 6.2 million market capitalization as of October 15, 2026.

NCNA, US67022C3043, Illustration mit AI erstellt.

NuCana plc (ISIN US67022C3043) won a European patent for its cancer candidate NUC-7738 on September 30, 2026. The patent takes the drug's worldwide protection beyond 85 issued patents, while the company's cash resources are expected to fund planned operations into 2029, according to GlobeNewswire.

Patent coverage reaches 85

The European Patent Office granted composition-of-matter patent EP 3683225 for the chemical structure of NUC-7738. NuCana said on September 30, 2026 that the candidate was being evaluated in the Phase 2 part of a Phase 1/2 study, including a combination with pembrolizumab in patients with PD-1 inhibitor-resistant metastatic melanoma.

The patent is an intellectual-property milestone rather than a commercial launch. NUC-7738 still sits in clinical development, so the value of the protection depends on trial progress, regulatory decisions and eventual market approval. NuCana is also developing NUC-3373, a targeted thymidylate synthase inhibitor, according to the company release.

What does the runway mean?

The financial backdrop remains central for a clinical-stage biotechnology company. NuCana reported a net loss of USD 3.08 million for the second quarter of 2026, according to Investing.com. That result gives the patent update a clear investor context: the company is extending its development timeline while continuing to consume cash before generating commercial revenue.

The next clinical milestones therefore matter more than the patent count alone. NuCana's investor-relations page lists the October 2026 corporate presentation and identifies the September patent announcement as its latest news item, while the second-quarter report was published on August 13, 2026.

NCNA stays a development-stage stock

NuCana was valued at USD 6.2 million on October 15, 2026, based on its latest Nasdaq market data. The stock's 52-week range was USD 0.95 to USD 5.65, placing the current valuation near the lower end of that span and underlining how strongly clinical progress can shape the equity story.

On Nasdaq, NCNA was last at USD 1.02 on October 15, 2026 at 4:00 p.m. ET in an after-hours quote. The company remains a clinical-stage biopharmaceutical developer whose investment case rests on NUC-7738, NUC-3373 and the funding runway described in its September 30, 2026 release.